Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL112 in acute coronary syndrome after myocardial infarction
NL-OMON54553Phase 3Recruiting
- Sponsor
- CSL Limited
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) and myocardial infarction (MI) comparing CSL112 with Placebo (2 arms). Primary endpoint: Time to first major adverse cardiovascular event through 90 days. Started Jan 2019; status: recruiting.
02
Drugs
CSL112
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON54553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54553.